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Molecular Profiling of the Metaplastic Spindle Cell
Carcinoma of the Breast Reveals Potentially
Targetable Biomarkers
Semir Vranic,1 Phillip Stafford,2 Juan Palazzo,3 Faruk Skenderi,4 Jeffrey Swensen,2
Joanne Xiu,2 David Spetzler,2 Zoran Gatalica2
Abstract
Spindlecell carcinoma isa raresubtypeofmetaplasticbreast cancer,with triple-negative phenotype. Twenty-three
spindle cell carcinomas were comprehensively explored for biomarkers of immuno-oncology and targeted ther-
apies using immunohistochemistry and DNA/RNA sequencing. Spindle cell carcinomas are characterized by
targetablemolecular alterations in themajority of cases, but, owing to the lackofuniformfindings, individual patient
profiling is necessary.
Introduction: Spindle cell carcinoma is a rare subtype of metaplastic breast cancer, with triple-negative (TNBC: estrogen
receptor-negative/progesterone receptor-negative/human epidermal growth factor receptor 2-negative) phenotype. It is
associated with a marked resistance to conventional chemotherapy and has an overall poor outcome. Materials and
Methods: Twenty-three pure spindle cell carcinomas of the breast (18 primary and 5 recurrent/metastatic) were
comprehensively explored for biomarkers of immuno-oncology and targeted therapies using immunohistochemistry and
DNA/RNA sequencing. Results: The majority (21/23) of spindle cell carcinomas were TNBC. Estrogen and androgen
receptor expression above the therapeutic thresholds were detected in 2 cases each. Pathogenic gene mutations were
identified in 21 of 23 cases, including PIK3CA, TP53, HRAS, NF1, and PTEN. One case with matched pre- and post-
chemotherapy samples exhibited a consistent mutational profile (PIK3CA and HRAS mutations) in both samples.
Gene amplifications were present in 5 cases, including 1 case without detectable mutations. The spindle cell carcinomas
cohort had consistently low total mutational burden (all below the 80th percentile for the entire TNBC cohort). All tumors
were microsatellite stable. Programmed death-ligand 1 expression was observed on both tumor cells (in 7/21 cases),
and in tumor-infiltrating immune cells (2/21 cases). Conclusions: Spindle cell carcinomas are characterized by
targetable molecular alterations in the majority of cases, but owing to the lack of uniform findings, individual patient
profiling is necessary. Detection of individual combinations of biomarkers should improve treatment options for this rare
but aggressive disease.
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Introduction
Metaplastic breast carcinoma (MBC) is a rare breast cancer
subtype, constituting w1% of all invasive breast cancers.1 Histo-
logically, MBC is a highly heterogeneous disease, encompassing
6 different morphologic subtypes, including spindle, squamous,
chondroid, osseous, rhabdomyoid, and mixed morphology.1 So-
matic mutations in TP53, PI3K MAPK, RB1, and Wnt pathways
genes have been frequently described in MBCs.2-11 MBCs are basal-
like and claudin-low breast cancers with a triple-negative phenotype:
estrogen receptor (ER), progesterone receptor (PR), and human
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epidermal growth factor receptor 2 (HER2/neu)-negative.7,9,12-14
With rare exceptions (low-grade adenosquamous and fibromatosis-
like metaplastic variants), MBCs are associated with a high recur-
rence/metastasis risk, chemotherapy resistance, and poor outcome.15
Mutational diversity is reflected in the morphologic heterogeneity
of MBCs; PIK3CA mutations were detected in all morphologic
variants of MBCs, excluding the chondroid variant,5,6,11 whereas
TERT mutations were more prevalent in spindle cell and squamous
variants.5 Microarray expression-based studies also revealed differ-
ences between the morphologic subtypes of MBC in regards to
epithelial-mesenchymal transition (EMT)-related genes such as
CDH1 and EPCAM.7
Programmed death-ligand 1 (PD-L1) expression in cancer and/or
immune cells, as a predictor of response to immune checkpoint
inhibitors, has also been described in a subset of MBCs.3,9,11,16,17
Pure spindle cell variants of MBC constitute < 10% of all
MBCs; the spindle cell pattern is usually seen within a mixed MBC
that constitutes w70% of all MBC morphologies. In the present
study, we explored a cohort of pure (> 90% of invasive tumor)
spindle cell MBC for the biomarkers of response to immuno-
oncology (I-O) and targeted therapies.
Materials and Methods
Case Selection
Twenty-three pure (> 90%) spindle cell MBC identified among
cases submitted to Caris Life Sciences (Phoenix, AZ) for molecular
profiling were investigated in the present study. Each case under-
went confirmation of the histologic diagnosis, including review of
the diagnostic immunohistochemical test results performed at the
referring pathology laboratory, by a board-certified pathologist
(Z.G.) at Caris Life Sciences.
Caris Life Sciences de-identified all reports and remnant spindle cell
carcinoma samples provided by the referring laboratories. Given that
the remnant tissues from previous samplings with no associated iden-
tifiers were used, this research was compliant with 45 CFR 46.101(b).
Therefore, the present study was deemed exempt from Institutional
Review Board approval, and consent requirements were waived.
Immunohistochemistry (IHC)
IHC assays included ER, PR, androgen receptor (AR), HER2/neu,
PD-L1, and pNTRK. In selected cases, PTEN, cKit, and E-cadherin
stains were done (the list of antibodies, clones and thresholds for
positivity are provided in Supplemental Table 1 [in the online
version]).
Next-generation Sequencing (NGS)
The samples were profiled using massively parallel sequencing
(NGS) of exons from 592 genes (SureSelect XT, Agilent, Santa Clara,
CA and the NextSeq instrument, Illumina, San Diego, CA).18
The tumor mutational burden (TMB) was assessed by calculating
the number of nonsynonymous missense mutations, excluding
common germline variants, in one megabase of DNA. TMB was
considered high if  11 mutations/megabase (muts/Mb) were
detected. The estimated threshold was based on a cohort of 603
TNBC cases using an 80th percentile cutoff value as recently sug-
gested by Samstein et al.19 Microsatellite instability (MSI) was
calculated from the NGS data by direct analysis of short tandem
repeat tracts in the target regions of sequenced genes. The count
only included alterations that resulted in increases or decreases in
the number of repeats; high microsatellite instability (MSI-H) was
defined as  46 altered microsatellite loci. This threshold was
established by comparing NGS with the polymerase chain reaction-
based microsatellite fragments analysis results from w2100
samples.18,20,21
Copy number variations were explored by comparing the depth
of detected NGS sequence reads to reads from a diploid control.
Genes having  6 copies were considered amplified.18
The ArcherDx FusionPlex Assay (ArcherDX, Boulder, CO) was
used for the gene fusion assessment. The gene fusion panel (n ¼ 54)
is available here: https://www.carismolecularintelligence.com/wp-
content/uploads/2017/03/TN0276-v14_Profile-Menu.pdf.
Results
Clinicopathologic Characteristics of the Cohort
Clinicopathologic data are summarized in Table 1.
The study included 23 spindle cell MBCs, of which 18 were
primary (17 from the breast and one from axilla) and 5 were
recurrent/metastatic cases.
All patients were female, with a mean age of 60.2 years (range,
30-83 years). With the exception of 1 case, all were grade 3 carci-
nomas (Nottingham modification of Bloom-Richardson system),
and the majority (21/23) were triple negative. ER and AR (2 cases
each) expressions above the therapeutic thresholds of 1% and 10%,
respectively, were rarely observed. HER2/neu was uniformly nega-
tive in all cases (0%) (Table 1).
Genomic Profile of Spindle Cell Carcinomas
Genomic alterations were detected in 22 of 23 cases: Twenty-one
cases had pathogenic mutations, whereas 1 case (#11) that was
devoid of any detectable pathogenic mutation harbored multiple
gene amplifications including KDR (VEGFR2), KIT, PDGFRA,
FIP1L1, and CHIC2. Only 1 case (#15) harbored no detectable
genomic alterations (Table 1).
Mutations most frequently affected PIK3CA (10/23, one case was
ERþ), TP53 (6/23), HRAS and NF1 (4/23 each), and PTEN (3/23)
(see Supplemental Table 2 in the online version).
Two cases exhibited evidence of EMT. The first case (#19)
(Table 1) was apocrine ductal carcinoma in situ transitioning into
spindle cell carcinoma. Upon separate microdissection analyses,
both in situ and invasive components harbored identical mutational
profiles (PTEN p.E242fs and HRAS p.Q61K mutations). EMT was
further evidenced by the loss of E-cadherin and beta-catenin
expression in the invasive spindle cell component; however, no
mutations were detected in the CDH1 or CTNNB1 genes, sug-
gesting possible epigenetic silencing.22 AR was positive in an
apocrine ductal carcinoma in situ, but not an invasive spindle cell
component. In the second case (#21) (Table 1), a morphologic
transition from ductal carcinoma not otherwise specified (NOS) to
spindle cell carcinoma was observed. The tumor also harbored a
PTEN mutation (c.1027-1G>A) and additional PIK3CA
(p.E542K) and CDH1 gene mutations (p.E243K, likely pathogenic
without E-cadherin protein loss) in both components.
One case with available matched pre- and post-chemotherapy
samples exhibited a consistent mutational profile (PIK3CA and
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HRAS mutations) in both samples. Similarly, another matched case
(primary breast and metastatic sample from the lung) had identical
mutational profiles at both sites (PIK3CA and KDM6A mutations).
None of the tested spindle cell carcinomas (n ¼ 9) exhibited
pNTRK positivity by IHC, including a case with NTRK1 gene
amplification (Table 1). No NTRK gene fusions or any other fusions
were detected in any of the successfully tested cases (n ¼ 14).
Gene amplifications were detected in 5 of 12 evaluable cases.
Two spindle cell carcinomas harbored CCND1 (encodes cyclin D1
protein) gene amplification. Both cases also had multiple gene
amplifications within the fibroblast growth factors family (FGF3,
FGF4, FGF19, and fibroblast growth factor receptor 3 (FGFR3)
(Table 1 and Supplemental Table 3 [in the online version]).
I-O Biomarkers in Spindle Cell Carcinomas
The spindle cell carcinomas consistently expressed a low TMB of
between 3 and 10 muts/Mb. Additionally, all spindle cell carci-
nomas were microsatellite stable (MSS).
One-third (7/21) of the spindle cell carcinomas expressed PD-L1
above the 1% threshold in cancer cells (Figure 1, Case #18, upper
images); 3 exhibited diffuse PD-L1 expression in cancer cells
(50%-100% cancer cell positive) (Figure 1A and B). In contrast,
PD-L1 expression in immune cells was observed in only 2 cases;
both were triple negative (Figure 1, Case #21, lower images).
Discussion
Recent studies have identified mutations in the TP53, PI3K
MAPK, RB1, and Wnt pathways as the most frequent somatic
mutations in MBCs.2-11 Our data confirm that spindle cell MBC
shares similar molecular features with other morphologic subtypes
of MBCs.6,9-11,23 PIK3CA mutations are particularly relevant
because the ESMO Scale for Clinical Actionability of Molecular
Targets (ESCAT) classified them as strong predictors of response to
PIK3CA inhibitors (level IA) (see Supplemental Table 2 in the
online version).24,25 Furthermore, the United States Food and Drug
Administration (FDA) recently approved the PIK3CA inhibitor










#1 Primary (3) Unknown Negative Negative BRAF None
#2 Primary (3) Unknown ERþ (1%) Negative TP53
#3 Primary (3) pT2NoMx Negative Positive (TCþ) PIK3CA, HRAS
#4 Primary (3) Unknown Negative Negative KDM6A
#5 Primary (axilla) (3) pT3NoMx ARþ (10%) Negative TP53, PIK3CA, NF1 MLLT1
#6 Primary (recurrent) (3) rpT3NoMx Negative Negative TP53, NF1
#7 Primary (3) pT3NoMx Negative Negative NF1
#8 Primary (3) pT2NoMx Negative Negative NF1, PIK3R1, BRIP1
#9 Primary (3) Unknown ARþ (15%) Positive (TC) TP53, RB1, PTEN
#10 Primary (recurrent) (3) Unknown Negative n/a TP53 CYP2D6
#11 Primary (3) pT3NxMx Negative n/a None KDR (VEGFR2), KIT b,
PDGFRA, FIP1L1,
CHIC2
#12 Metastatic (3) M1 Negative Positive (TC) TP53




ypT4NoMx Negative Positive (TC) PIK3CA None
#15 Primary (3) pT2NoMx Negative Negative None None
#16 Metastatic (3) M1 Negative Negative KRAS
#17 Primary (3) Unknown Negative Negative PIK3CA
#18 Primary (3) pT4bNxMx Negative Positive (TC) PIK3CA, HRAS




ypT1cNoMx Negative Negative PIK3CA, HRAS AKT2, CCND1, FGF3,
FGF4, FGFR3, NTRK1b
#21 Primary (3) pT2N1aMx Negative Positive (IC) PIK3CA, PTEN, CDH1
E243K
None
#22 Primary (3) Unknown Negative Positive (IC) PIK3CA E545K; NF2
V219fs
None
#23 Primary and meta
(matched) (3)
M1 Negative Positive (100% TC) PIK3CA Q546K,
KDM6A E1381
None
Abbreviations: AJCC ¼ American Joint Committee on Cancer; AR ¼ androgen receptor; ER ¼ estrogen receptor; IC ¼ immune cells; n/a ¼ not available; NGS ¼ next-generation sequencing;
PD-L1 ¼ programmed death-ligand 1; PR ¼ progesterone receptor; TC ¼ tumor cells.
aOnly pathogenic mutations are listed.
bBoth cases were further tested by immunohistochemistry (CD117 and panTRK antibodies) and were negative.
cMatched core and surgical biopsy were tested; this cancer was treated with neoadjuvant chemotherapy but the tumor was chemoresistant.
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Piqray (alpelisib) for the treatment of ERþ and PIK3CA-mutated,
advanced, or metastatic breast cancer following progression on, or
after an, endocrine-based regimen. One of the PIK3CA-mutated
spindle cell carcinomas from our series was ERþ. In addition, several
clinical trials and case studies have revealed promising effects of
PIK3CA/mammalian target of rapamycin (mTOR) inhibitors in
patients with advanced/metastatic MBC that harbor mutations in
the PI3K pathway.11,23,26-28 Basho et al demonstrated that mTOR
inhibitors (temsirolimus or everolimus) combined with doxorubicin
and bevacizumab were more effective in the treatment of MBC than
in non-MBC.28 Similarly, Moulder et al showed the effectiveness of
mTOR inhibitors (temsirolimus) in the treatment of MBC.23 In
short, the presence of PIK3CA, PIK3R1, and PTEN mutations in
w60% of spindle cell MBC may be a potential therapeutic guide
for a substantial proportion of these carcinomas.6
Mutations in HRAS were observed in 17% of the spindle cell
MBCs, 3 of which had a coincident PIK3CA mutation. HRAS
mutations have been well described in other breast cancer subtypes
including MBCs.2,3,10,29,30 Interestingly, co-occurring HRAS and
PIK3CA mutations have recently been recognized as driver muta-
tions in both benign and malignant adenomyoepitheliomas of the
breast.31,32 In cell culture models, the HRAS p.Q61R mutation
appears to drive neoplastic transformation of breast cancer cells
followed by reduced E-cadherin expression, increased myoepithelial
differentiation, and activation of the Akt/PIK3CA pathway. These
features, commonly seen in MBC,32 underlie the phenotypic sim-
ilarities between the 2 entities.33 In our cohort, we clearly
demonstrated the EMT in 2 cases (#19 and #21).
Our study also revealed NF1 gene mutations in a proportion of
spindle cell carcinomas. NF1 germline mutations are responsible for
neurofibromatosis type 1 (OMIM#162200), whereas somatic NF1
mutations have been described in various cancers including breast
cancer.4,34 Several previous studies have identified NF1 mutations
in MBC, including germline mutations in patients with neurofi-
bromatosis type 1.4,10,35-40 Our findings provide further evidence of
a role for the NF1 gene in a subset of MBC.
Recently, the FDA approved I-O therapy with atezolizumab for
TNBC containing  1% PD-L1 positive immune cells (ICs) in the
tumor biopsy, based on the IMpassion130 clinical trial
(NCT02425891). We found that one-third of spindle cell MBC
expressed PD-L1; however, it was predominantly expressed in the
neoplastic, tumor cell (TC) component. This finding was in line with
our previous study ofMBC3 and a study byDill et al.16 Only 2 cases in
the current study clearly expressed PD-L1 solely in the IC component
of the tumor above the companion diagnostics threshold of 1%. For
atezolizumab, the predictive PD-L1 expression is found in ICs (in
Figure 1 Two Triple-negative Spindle Cell Carcinomas With PD-L1 Positivity: Case #18 (Upper 2 Figures) With Diffuse (70%) PD-L1
Expression in Cancer Cells (TCs); Case #21 (Lower 2 Figures) Showing PD-L1 Positivity at 1% in ICs (Red Arrows). The
Left-sided Images Represent Hematoxylin and Eosin Stained Slides; Both Cases Were Tested With VENTANA PD-L1 (SP142)
Assay, a United States Food and Drug Administration-Approved Test
Abbreviations: IC ¼ immune cells; PD-L1 ¼ programmed death-ligand 1; TC ¼ tumor cells.
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tumors expressing  1% area occupied by PD-L1þ IC), not in TCs
expressing PD-L1. This is in contrast to a case study of Adams et al,
who revealed an impressive clinical response in a patient with TC
PD-L1-positive (22c3 clone) advanced MBC treated by combined
anti-PD-1 therapy with pembrolizumab and nab-paclitaxel.17 Simi-
larly, Al Sayed et al reported a complete response to the combination of
a novel anti-PD-L1 antibody, durvalumab, with paclitaxel in a patient
with chemoresistant, metastatic MBC whose neoplastic cells overex-
pressed PD-L1.41
In our study, 2 PD-L1-positive (one in TC and IC, respectively)
spindle cell carcinomas harbored PTEN mutations. PTEN muta-
tions in cancer cells may induce immunosuppressive expression
signatures and the lack of response to anti-PD-1 therapies.42 Taken
together, PD-L1 status in various subgroups of MBC needs to be
precisely determined (cell type expressing PD-L1) in the context of
additional mutational data (eg, PTEN ) and may not unequivocally
predict response to I-O therapy. Other lineage-agnostic predictive
biomarkers for immune checkpoint inhibitors (TMB and MSI
status) were negative (low TMB and MSS) in our series of spindle
cell carcinomas, similar to the studies of Ng et al6 and Tray et al.9
TMB and MSI status in spindle cell carcinomas are also comparable
with the data from our large cohort of > 3000 patients with TNBC
NOS that exhibited a very low frequency of MSI-H and high
TMB.43
Determination of the AR status in TNBC is important, and
positivity has been reported in various subtypes of breast cancer
including both TNBC NOS and MBC.2,44 Two spindle cell car-
cinomas from our cohort were also AR-positive. A phase II clinical
trial by Gucalp et al reported AR positivity at 12% among TNBC.44
A clinical benefit rate was seen in 19% of the patients treated with
the anti-AR drug bicalutamide.44 Another study conducted on 116
patients with TNBC revealed a significant clinical activity of enza-
lutamide in patients with advanced AR-positive TNBC.45
Although we found CCND1 and FGF family genes (FGF3,
FGF4, FGF19, and FGFR1) amplified in a proportion of spindle
cell carcinomas, these genes appear not to be reliable predictors of
response to their respective inhibitors in breast cancer.24 Therefore,
the ESCAT categorized these biomarkers as “Tier X,”24 and their
clinical relevance in spindle cell carcinomas remains unclear.
In conclusion, spindle cell carcinomas are characterized by
targetable molecular alterations in the majority of cases, but, owing
to the lack of uniform findings, individual patient profiling is
necessary. Detection of individual combinations of biomarkers
should improve treatment options for this rare but aggressive
disease.
Clinical Practice Points
 The majority of spindle cell carcinomas have triple negative
phenotype.
 The molecular profile is similar to that of other subtypes of
metaplastic breast carcinomas.
 The molecular alterations within the PIK3CA pathway along
with PD-L1 expression characterize a proportion of spindle cell
carcinomas and may guide targeted treatments for this rare
disease.
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Supplemental Data
Supplemental Table 1 The List of Antibodies, Clones and











Androgen receptor (AR) AR27 (Leica Biosystems) >10%2-4
HER-2/neu 4B5 (Ventana) >10% at 3 þ intensity5
PD-L1 SP142 (Ventana) 1% of the tumor area
(TNBC) or at  1% of
cancer cells for non-
TNBC6,7
pNTRK EPR17341 (Abcam) 1%8
PTEN 6H2.1 (Dako Agilent) Any positivity
E-cadherin EP700Y (Cell Marque) Any positivity
c-Kit (CD117) 9.7 (Ventana) Any positivity
Abbreviations: HER2 ¼ Human epidermal growth factor receptor 2; PD-L1 ¼ programmed
death-ligand 1; TNBC ¼ triple negative breast cancer.
Supplemental Table 2 The Frequency of Genomic Alterations
in Spindle Cell Carcinomas According
to the Levels of Evidence (LOE) as
Recommended by the ESMO Scale for












PIK3CA mutations 10/23 (43) IA
PTEN loss (mutations) 3/23 (13) IIA
NF1 mutations 4/23 (17) IVA
PIK3R1 mutations 1/23 (4) IVA
CDH1 mutations 1/23 (4) IVA
TP53 mutations 6/23 (26) IVA
IA ¼ “Alteration-drug match is associated with improved outcome in clinical trials” (prospective
randomized study).
IIA ¼ “Alteration-drug match is associated with antitumor activity, but magnitude of benefit is
unknown” (retrospective studies).
IVA ¼ “Pre-clinical evidence of actionability” (in vitro and in vivo models).
aBased on the ESCAT (ESMO Scale for Clinical Actionability of Molecular Targets) evidence tier
(references: Ann Oncol 2018; 29:1895-902; Ann Oncol 2019; 30:365-73).
Supplemental Table 3 A List of Genomic Alterations in Spin-
dle Cell Carcinomas for Which Clinical






% in Spindle Cell
Carcinomas,
n/N (%) Tier X Alterationsa
CCND1 amplification 2/12 (17) Not actionable
FGF genes amplification 2/12 (17) Not actionable
aTier X indicates genomic alterations that are not clinically proven as targetable.
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